Details checkedClinical trial listing onlyCheckedregistry

Pimozide for post-COVID tinnitus by Applied Biology

Also known as: Pimozide, Pimozide 1 MG, JW-COVID-DRG-001, NCT05507372

Applied Biology, Inc.

Primary source

Company

Applied Biology, Inc.

Program Type

Therapeutic

Modality

Small Molecule

Stage

Interventional/NA

Status

Unknown

Target Gene

—

Route / Mode

Oral tablet

Confidence

78%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Unknown

Population

adult, tinnitus, post-covid

Trial IDs

Mechanism

Oral dopamine receptor antagonist evaluated for subjective tinnitus associated with post-acute COVID-19 syndrome.

Indications

Tinnitus Post-COVID Tinnitus

Notes

Verified as an Applied Biology/Jupiter Wellness-sponsored randomized pimozide study for post-COVID tinnitus. Registry status is stale: last known not-yet-recruiting in 2022 with estimated dates now in the past, so current status remains Unknown.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, stage, status, route, indications...

IDs: NCT05507372, JW-COVID-DRG-001

Open

Key Events

2022-08-19

Pimozide post-COVID tinnitus study first posted

Clinical Trials (1)

NCT05507372

Data Checks

registry-status-staleno-posted-results-confirmedno-sites-listed-in-registry

Related Programs

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

AC102 by AudioCure Pharma

Company: AudioCure Pharma · Small Molecule · Phase 2

SPI-1005 by Sound Pharmaceuticals

Company: Sound Pharmaceuticals · Small Molecule · Phase 3

ACOU085 by Acousia Therapeutics

Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2

CIL001 (Paliroden) by Cilcare

Company: Cilcare SAS · Small Molecule · Phase 1/2